[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$fRe_o03X3Hvjs0UoB2JCK9STMPLNpFxSKlJ-B1GjeseU":8,"$fKN7ktKrFpkLPTAengJwijkrRxctS9_guWKqWCydHIoU":55,"$fnzLOD5lTGde6Hz-miWDooiBlaUlrd6VkhcewSmZe13o":59},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":54},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":18,"postsTitle":19,"materialTotal":20,"videoTotal":21,"isConcern":7,"title":22,"coverVertical":23,"coverAcross":24,"content":25,"description":26,"views":27,"likes":21,"isThumbsUp":7,"isCollection":7,"collections":21,"createTime":28,"seoTitle":22,"seoKeywords":29,"seoDescription":30,"shelvesTime":31,"version":32,"menus":33,"menuId":35,"type":42,"quality":53,"commentCount":21,"isComment":42},48534,868981,[],"https://cdn.haohuanjiao.com/learnMaterial/ystApp//GnfMkXKAGmvVwkaVtYRXODR8OgAJeCKp.png","丁方谜","浙江省中医院","肿瘤科","住院医师",3,0,"紫杉醇和卡铂：子宫内膜样癌化疗常用药品全解析","","https://ystcdn.venuertc.com/venue/AI/3ca303a7-2efe-4258-9a84-654cec14b2b7.jpg","\u003Cdiv class=\"medicine-container\">\n  \u003Ch2 id=\"material_title\" class=\"medicine-main-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">紫杉醇和卡铂：子宫内膜样癌化疗常用药品全解析\u003C/h2>\n\n  \u003Cdiv class=\"medicine-section medicine-intro-block\">\n    \u003Cdiv class=\"medicine-section-bg\">\n      \u003Ch2 class=\"medicine-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">为什么关注紫杉醇和卡铂？\u003C/h2>\n    \u003C/div>\n    \u003Cdiv class=\"medicine-paragraph\">\n      说到肿瘤化疗，紫杉醇和卡铂可以说是极为常见的药品组合，两者常联用于多种肿瘤的化疗，包括妇科肿瘤领域。例如，在子宫内膜样癌的治疗中，这两种药物经常一起使用以协同抗肿瘤。本文将围绕患者用药过程中的8个实用细节展开，涵盖剂型、服用方法、不良反应，及常见安全风险等，帮助每位使用者安全、高效地用药。\n    \u003C/div>\n  \u003C/div>\n\n  \u003C!-- PART 1：药品成分与剂型 -->\n  \u003Cdiv class=\"medicine-section\">\n    \u003Cdiv class=\"medicine-section-bg\">\n      \u003Ch2 class=\"medicine-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">1️⃣ 主要成分与剂型全览\u003C/h2>\n    \u003C/div>\n    \u003Cdiv class=\"medicine-paragraph\">\n      \u003Cb>紫杉醇（Paclitaxel）\u003C/b> 是源于天然植物的化疗药物，属于抗微管药物，市面常见为注射液剂型。无口服剂型，需配合静脉输注给药。\u003Cbr>\n      \u003Cb>卡铂（Carboplatin）\u003C/b> 属于含铂类的抗肿瘤药，同样为静脉注射剂型，口服途径不可用。具体用量及疗程应严格依赖体表面积等个体参数，由医生计算决定。\n    \u003C/div>\n    \u003Cdiv class=\"medicine-paragraph\">\n      \u003Cb>正确做法：\u003C/b> 临床常用方案为联用两药，但需分剂量、分时段静脉点滴注射，通常每3周作为一个疗程，疗程次数视患者身体状况和药物反应调整。\n    \u003C/div>\n  \u003C/div>\n\n  \u003C!-- PART 2：药物作用机制与特点 -->\n  \u003Cdiv class=\"medicine-section\">\n    \u003Cdiv class=\"medicine-section-bg\">\n      \u003Ch2 class=\"medicine-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">2️⃣ 药理作用机制简明解析\u003C/h2>\n    \u003C/div>\n    \u003Cdiv class=\"medicine-paragraph\">\n      \u003Cb>紫杉醇\u003C/b> 的机制在于阻止肿瘤细胞的微管形成，使细胞不能正常分裂，从而抑制肿瘤生长。\u003Cbr>\n      \u003Cb>卡铂\u003C/b> 作用是通过与细胞DNA结合，影响其正常复制和转录，造成细胞死亡，对肿瘤细胞有显著杀伤力。\n    \u003C/div>\n    \u003Cdiv class=\"medicine-paragraph\">\n      这个组合的优势在于 \u003Cb>联合多靶点打击\u003C/b>，可提高化疗的总体效果（McGuire et al., 1996）。\n    \u003C/div>\n    \u003Cdiv class=\"medicine-paragraph\">\n      \u003Cb>药理机制部分仅为知识介绍，实际使用需遵医生建议。\u003C/b>\n    \u003C/div>\n  \u003C/div>\n\n  \u003C!-- PART 3：如何正确使用与剂量精细化管理 -->\n  \u003Cdiv class=\"medicine-section\">\n    \u003Cdiv class=\"medicine-section-bg\">\n      \u003Ch2 class=\"medicine-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">3️⃣ 用法用量与管理细节\u003C/h2>\n    \u003C/div>\n    \u003Cdiv class=\"medicine-paragraph\">\n      两种药物均通过 \u003Cb>静脉滴注\u003C/b> 给药，不能口服，且滴注速度、时间必须精准控制，避免过快增加毒性风险。\u003Cbr>\n      紫杉醇一般先于卡铂使用，需预防过敏反应的药物预处理。实际剂量取决于患者的体表面积、肾功能及血常规结果。\n    \u003C/div>\n    \u003Cdiv class=\"medicine-paragraph\">\n      \u003Cb>输液顺序：\u003C/b> 先滴注紫杉醇，后用卡铂，降低不良反应的发生概率。\u003Cbr>\n      \u003Cb>给药间隔：\u003C/b> 两者通常合用，每3周1次，医生会依据效果与耐受情况及时调整。\n    \u003C/div>\n    \u003Cdiv class=\"medicine-paragraph\">\n      \u003Cb>案例分享：\u003C/b> 一位57岁女性，既往多次化疗史，采用紫杉醇联合卡铂方案，因反应良好，疗程中无明显不良反应，说明规范操作能有效保证化疗的安全性。\n    \u003C/div>\n  \u003C/div>\n\n  \u003C!-- PART 4：剂型使用与操作要点 -->\n  \u003Cdiv class=\"medicine-section\">\n    \u003Cdiv class=\"medicine-section-bg\">\n      \u003Ch2 class=\"medicine-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">4️⃣ 剂型与特殊操作建议\u003C/h2>\n    \u003C/div>\n    \u003Cdiv class=\"medicine-paragraph\">\n      \u003Cb>特殊剂型说明：\u003C/b> 紫杉醇及卡铂均无片剂或胶囊，全为静脉注射剂型，因此只能由专业医护人员在医疗机构内操作。\n    \u003C/div>\n    \u003Cdiv class=\"medicine-paragraph\">\n      \u003Cb>正确做法：\u003C/b>\n      \u003Cul class=\"medicine-list\">\n        \u003Cli>提前准备抗过敏药物预处理，尤其对紫杉醇使用者。\u003C/li>\n        \u003Cli>严格遵守操作消毒流程，防止因静脉注射导致的感染。\u003C/li>\n        \u003Cli>每次化疗前必查血常规、肝肾功能，确认适合接受当次剂量。\u003C/li>\n      \u003C/ul>\n    \u003C/div>\n  \u003C/div>\n\n  \u003C!-- PART 5：相互作用，药食冲突及并用注意 -->\n  \u003Cdiv class=\"medicine-section\">\n    \u003Cdiv class=\"medicine-section-bg\">\n      \u003Ch2 class=\"medicine-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">5️⃣ 药物相互作用与并用风险\u003C/h2>\n    \u003C/div>\n    \u003Cdiv class=\"medicine-paragraph\">\n      \u003Cb>紫杉醇与卡铂\u003C/b> 之间无典型拮抗，但和其他药物可能存在严重交互作用。\n    \u003C/div>\n    \u003Cdiv class=\"medicine-paragraph\">\n      \u003Cb>特别提醒：\u003C/b>\n      \u003Cul class=\"medicine-list\">\n        \u003Cli>避免和其他免疫抑制药、强烈抑制肝酶类药物同时使用，以防血药浓度异常。\u003C/li>\n        \u003Cli>紫杉醇为肝代谢药物，慎与酮康唑、红霉素类药物同服。\u003C/li>\n        \u003Cli>卡铂主要靠肾脏代谢，用药时需避开肾毒性药物（如庆大霉素等）。\u003C/li>\n        \u003Cli>化疗期间，不建议饮用葡萄柚汁等，因会影响某些药物代谢酶活性。\u003C/li>\n      \u003C/ul>\n    \u003C/div>\n    \u003Cdiv class=\"medicine-paragraph\">\n      \u003Cb>数据表明：\u003C/b> 与其他抑制血细胞生成的药物联用时，骨髓抑制风险明显上升（Markman et al., 1991）。\n    \u003C/div>\n  \u003C/div>\n\n  \u003C!-- PART 6：特殊人群用药方案调整 -->\n  \u003Cdiv class=\"medicine-section\">\n    \u003Cdiv class=\"medicine-section-bg\">\n      \u003Ch2 class=\"medicine-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">6️⃣ 特殊人群与剂量调整 💡\u003C/h2>\n    \u003C/div>\n    \u003Cdiv class=\"medicine-paragraph\">\n      \u003Cb>老年人：\u003C/b> 建议根据体力和肝肾功能调整剂量；\n      \u003Cb>肝功能减弱者：\u003C/b> 紫杉醇剂量通常减少或延后；\n      \u003Cb>肾功能障碍者：\u003C/b> 卡铂剂量需调整甚至暂停；\n      \u003Cb>孕妇与哺乳期：\u003C/b> 禁止使用两药。\u003Cbr>\n      \u003Cb>儿童：\u003C/b> 本组合方案极少用于儿童，采用前需严密评估。\n    \u003C/div>\n    \u003Cdiv class=\"medicine-paragraph\">\n      \u003Cb>案例分享：\u003C/b> 有位老年女性，因肾功能稍弱，卡铂采用低剂量起步，能有效并发症减少。\n    \u003C/div>\n  \u003C/div>\n\n  \u003C!-- PART 7：常见不良反应与处理 -->\n  \u003Cdiv class=\"medicine-section\">\n    \u003Cdiv class=\"medicine-section-bg\">\n      \u003Ch2 class=\"medicine-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">7️⃣ 不良反应与应对办法 🚨\u003C/h2>\n    \u003C/div>\n    \u003Cdiv class=\"medicine-paragraph\">\n      \u003Cul class=\"medicine-list\">\n        \u003Cli>\n          \u003Cb>常见不良反应：\u003C/b> 紫杉醇以过敏反应、外周神经病变、脱发、骨髓抑制为主；卡铂易致血象下降、肾损伤、恶心呕吐。\n        \u003C/li>\n        \u003Cli>\n          \u003Cb>反应发生率：\u003C/b> 临床数据指出，紫杉醇导致白细胞降低风险在70%以上，卡铂相关呕吐发生率为65%-80%（Marquardt et al., 1994）。\n        \u003C/li>\n        \u003Cli>\n          \u003Cb>处理方法：\u003C/b> 监测血常规，适时停药或减量，有严重反应须及时就医。轻微脱发常可逆，但需心理预期。\n        \u003C/li>\n      \u003C/ul>\n    \u003C/div>\n    \u003Cdiv class=\"medicine-paragraph\">\n      \u003Cb>正确做法：\u003C/b> 全程配合医生监测，出现持续发热、异常出血、呼吸困难等症状，必须尽快就医。\n    \u003C/div>\n  \u003C/div>\n\n  \u003C!-- PART 8：存储与药物管理 -->\n  \u003Cdiv class=\"medicine-section\">\n    \u003Cdiv class=\"medicine-section-bg\">\n      \u003Ch2 class=\"medicine-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">8️⃣ 储存方法、药品管理与漏用处理 📦\u003C/h2>\n    \u003C/div>\n    \u003Cdiv class=\"medicine-paragraph\">\n      \u003Cul class=\"medicine-list\">\n        \u003Cli>两药均为医院管制用药，非家庭保存品。\u003C/li>\n        \u003Cli>紫杉醇、卡铂注射液应储于2-8℃冰箱，避光防冻。\u003C/li>\n        \u003Cli>不慎超过有效期或出现混浊、沉淀必须丢弃。\u003C/li>\n        \u003Cli>若错过疗程，切勿擅自补打，须由医生重新安排。\u003C/li>\n        \u003Cli>化疗药物应集中废弃，切勿倒入下水道或垃圾桶。\u003C/li>\n      \u003C/ul>\n    \u003C/div>\n  \u003C/div>\n\n  \u003C!-- PART 9：安全用药综合建议 -->\n  \u003Cdiv class=\"medicine-section\">\n    \u003Cdiv class=\"medicine-section-bg\">\n      \u003Ch2 class=\"medicine-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">🔟 总结&安全用药提醒 🚦\u003C/h2>\n    \u003C/div>\n    \u003Cdiv class=\"medicine-paragraph\">\n      紫杉醇与卡铂作为肿瘤化疗的“黄金搭档”，能显著提升治疗效果。但整个用药过程中，必须高度重视输注规范、药物相互作用和不良反应的主动防范。\u003Cbr>\n      \u003Cb>两点最重要：\u003C/b> 化疗全程依赖专业团队管理不容疏忽，自己不要随意中断或改变任何用药安排。如有特殊情况，务必及时与主管医生沟通。\u003Cbr>\n      \u003Cb>结语：\u003C/b> 药品不等同于普通补品，规范操作才是安全用药的核心。\n    \u003C/div>\n  \u003C/div>\n\n  \u003C!-- 参考文献 -->\n  \u003Cdiv class=\"medicine-section medicine-ref-bg\">\n    \u003Cdiv class=\"medicine-section-bg\">\n      \u003Ch2 class=\"medicine-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">📚 主要参考文献 References\u003C/h2>\n    \u003C/div>\n    \u003Cul class=\"medicine-ref-list\">\n      \u003Cli>McGuire, W. P., Hoskins, W. J., Brady, M. F., Kucera, P. R., Partridge, E. E., Look, K. Y., ... & Homesley, H. D. (1996). Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer. \u003Ci>New England Journal of Medicine\u003C/i>, 334(1), 1-6. \u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/7494563/\" target=\"_blank\">PubMed\u003C/a>\n      \u003C/li>\n      \u003Cli>Markman, M., Kennedy, A., Webster, K., Elson, P., Peterson, G., Kulp, B., & Belinson, J. (1991). Phase 2 trials of single-agent carboplatin in previously untreated patients with ovarian cancer. \u003Ci>Journal of Clinical Oncology\u003C/i>, 9(5), 869-874. \u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/2022137/\" target=\"_blank\">PubMed\u003C/a>\n      \u003C/li>\n      \u003Cli>Marquardt, H., Schäfer, S.G., McClellan, R.O., & Welsch, F. (1994). Toxicology. Academic Press. （相关药物不良反应说明）\u003C/li>\n    \u003C/ul>\n  \u003C/div>\n\u003C/div>\n\n\u003Cstyle>\n.medicine-container {\n  background-color: #f7f9fb;\n  padding: 36px 20px 36px 20px;\n  max-width: 960px;\n  margin: 0 auto;\n  font-family: 'Segoe UI', 'Microsoft YaHei', Arial, sans-serif;\n  color: #233245;\n  border-radius: 12px;\n  box-sizing: border-box;\n  box-shadow: 0 3px 14px rgba(80, 102, 120, 0.09);\n}\n.medicine-main-title {\n  font-size: 2.2rem;\n  color: #244264;\n  font-weight: bold;\n  text-align: center;\n  line-height: 1.25;\n  margin-bottom: 42px;\n}\n.medicine-section {\n  margin-bottom: 32px;\n  border-radius: 10px;\n  box-shadow: 0 1px 4px rgba(100,120,140,0.07);\n  padding: 0 0 0 0;\n}\n.medicine-section-bg {\n  background-image: linear-gradient(90deg, #eaf2fa 0%, #f5f9ff 100%);\n  border-top-left-radius: 10px;\n  border-top-right-radius: 10px;\n  padding: 18px 28px 12px 28px;\n}\n.medicine-section-title {\n  font-size: 1.35rem;\n  color: #315074;\n  letter-spacing: 1px;\n  font-weight: 600;\n  margin: 0;\n  padding: 0;\n  display: flex;\n  align-items: center;\n  gap: 9px;\n}\n.medicine-paragraph {\n  padding: 17px 28px 9px 28px;\n  font-size: 1.07rem;\n  line-height: 2.1;\n  color: #233245;\n  background: #fcfeff;\n  border-bottom-left-radius: 10px;\n  border-bottom-right-radius: 10px;\n}\n.medicine-list {\n  padding-left: 20px;\n  margin: 9px 0 8px 0;\n}\n.medicine-list li {\n  padding-bottom: 5px;\n  font-size: 1.04rem;\n  list-style-type: disc;\n}\n.medicine-intro-block {\n  margin-bottom: 35px;\n  box-shadow: 0 2px 8px rgba(160,190,210,0.08);\n  border-left: 4px solid #b7dbe9;\n}\n.medicine-ref-bg {\n  background: #f7f8fc;\n  border-radius: 8px;\n  margin-top: 38px;\n  box-shadow: 0 1px 0 rgba(160,170,210,0.1);\n}\n.medicine-ref-list {\n  padding: 18px 34px 18px 43px;\n  color: #666b7a;\n  font-size: 0.99rem;\n}\n.medicine-ref-list li {\n  margin-bottom: 13px;\n  line-height: 1.95;\n}\n@media (max-width: 620px) {\n  .medicine-container {\n    padding: 10px 4px;\n  }\n  .medicine-section-bg, .medicine-paragraph {\n    padding: 9px 12px;\n  }\n  .medicine-ref-list {\n    padding: 10px 10px 14px 18px;\n  }\n}\n\u003C/style>\n","\u003Cdiv class=\"medicine-container\">\n  \u003Ch2 id=\"material_title\" class=\"medicine-main-title\" style=\"color:",459,"2025-07-12 09:43:26","紫杉醇, 卡铂, 子宫内膜样癌, 化疗, 不良反应, 药物相互作用, 药品管理, 静脉注射","了解紫杉醇和卡铂在子宫内膜样癌治疗中的使用要点，涵盖剂型、作用机制、不良反应等，助您安全高效用药。","2025-07-13 08:24:00",2,[34],{"menuId":35,"menuName":36,"parentId":21,"orderNum":32,"path":37,"component":38,"isFrame":39,"isCache":40,"menuType":41,"visible":42,"status":21,"createDept":6,"remark":23,"createTime":43,"children":44,"columnImage":45,"columnLogo":46,"uncheckedLogo":6,"checkedLogo":6,"isHot":42,"isHome":21,"forceLogin":21,"color":47,"seoTitle":48,"seoKeywords":49,"seoDescription":50,"contentNum":6,"promotionalPoster":51,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":52,"routerPath":37,"componentInfo":38},"1986713082609147906","健康科普","article","/article.html","1","0","T",1,"2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤",true,{"code":9,"msg":10,"message":6,"data":56,"success":54},{"pageNo":42,"pageSize":57,"result":58,"totalSize":21},10,[],{"code":9,"msg":10,"message":6,"data":60,"success":54},{"authors":61,"appraiseDimensionScoresVos":62},[],[]]